Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological C… (NCT03372720) | Clinical Trial Compass
CompletedNot Applicable
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
United States19 participantsStarted 2018-05-11
Plain-language summary
This randomized pilot trial studies how well fractional carbon dioxide (CO2) laser therapy works in minimizing genitourinary syndrome of menopause (GSM) in gynecological cancer survivors. Fractional CO2 laser therapy may reduce symptoms of GSM in survivors of gynecologic cancers.
Who can participate
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women with cervical, endometrial, vaginal, vulvar or ovarian cancer who have completed all cancer related treatment \>= 6 months prior to enrollment
* Any form of hysterectomy, including radical hysterectomy permitted
* Must have no evidence of recurrent disease on pelvic exam within past 3 months
* Radiation therapy is permitted but not required
* Patient reported dyspareunia and/or vaginal dryness with severity of \>= 4 on a scale from 0 (none) to 10 (most severe) that has been persistent over \>= 4 weeks and/or the inability to be sexually active due to pain
Exclusion Criteria:
* Patients with recurrent or metastatic endometrial, vaginal, vulvar, cervical, or ovarian cancer
* Pelvic organ prolapse stage II or higher
* Prior reconstructive pelvic surgery involving mesh
* Hormone replacement therapy or vaginal estrogen therapy within 6 weeks prior to enrollment
What they're measuring
1
Change in genitourinary syndrome of menopause (GSM) symptoms
Timeframe: Baseline to 12 weeks
Trial details
NCT IDNCT03372720
SponsorOhio State University Comprehensive Cancer Center